Ann: Starpharma announces new CEO, Ms Cheryl Maley, page-28

45 is possibly interstate transfer fee?
The renumeration upfromnt and trailing for the IMO skillset supplied is way over the odds ?
Makes you wonder what you would have to pay for a candidate with IMO relevant track record , could bring insto investors onto the register via reputation, new board and let alone have CEO experience showing sucess at leading development ,approval , registration ,partnerships in pharma in small compoany with limited support and so on?

As for complaiance I do wonder how someone would not notice that the company they are a director of had not lodged a Initial directors interest for 5 months?

Can only hope for shareholders that there is a self awareness of any skills lacking and suitable professsioals can be aggregated and managed to fill in gaps to get SPL moving and subsequently communicating when decks are cleared but odd of that with current transittion structure? Just a massive learning curve IMO in so many critical areas at critical time and premium IMO has been paid?

Hope it works out for shareholders